JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Treatment Response Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease

  • 0University of California, Los Angeles.
Arthritis Care & Research +

|

December 23, 2024

|

December 23, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Changes in Krebs von den Lungen (KL)-6 levels predict progressive pulmonary fibrosis (PPF) in systemic sclerosis-associated interstitial lung disease (SSc-ILD) patients. This biomarker aids in personalizing SSc-ILD treatment strategies.

Area Of Science

  • Rheumatology
  • Pulmonology
  • Biomarker Discovery

Background

  • Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a significant cause of morbidity and mortality.
  • Predicting progressive pulmonary fibrosis (PPF) in SSc-ILD patients is crucial for timely therapeutic intervention.
  • Current predictive models for PPF require enhancement with dynamic biomarkers.

Purpose Of The Study

  • To investigate the predictive value of changes in circulating biomarkers for the development of PPF in SSc-ILD patients undergoing treatment.
  • To assess the utility of longitudinal biomarker measurements in refining PPF risk stratification.

Main Methods

  • Analysis of longitudinal biomarker data (CRP, IL-6, CXCL4, CCL18, KL-6) from Scleroderma Lung Study II participants.
  • Comparison of mycophenolate mofetil (MMF) versus cyclophosphamide (CYC) treatment arms.
  • Logistic regression modeling to evaluate the association between biomarker changes and PPF development by 24 months.

Main Results

  • Changes in Krebs von den Lungen (KL)-6 levels significantly correlated with PPF development (P < 0.001).
  • Elevated KL-6 changes were observed in patients who developed PPF, while decreases were seen in those who did not.
  • In the MMF arm, changes in C-reactive protein (CRP) and CXCL4 also correlated with PPF; change in KL-6 remained a significant predictor (OR 1.4; P = 0.0002) when added to baseline models.

Conclusions

  • Longitudinal changes in KL-6 levels effectively predict PPF in SSc-ILD patients treated with MMF or CYC.
  • KL-6 serves as a valuable dynamic biomarker for assessing fibrosis progression.
  • Incorporating KL-6 monitoring into clinical practice may enable personalized treatment strategies for SSc-ILD.